New opportunities in first-line therapy of unresectable EGFRm NSCLC. Overview of clinical trials FLAURA, FLAURA2, LAURA
Summary. On May 25th, a national scientific-practical conference with international participation titled «Diagnosis and Treatment of Lung Cancer. Transition to European Standards» was held. Associate Professor Yaroslav Shparyk, Head of the Chemotherapy Department at the Lviv Oncology Regional Treatment and Diagnostic Center, presented a report on «New Opportunities in the First-Line Therapy of Unresectable EGFRm NSCLC. Overview of Clinical Trials FLAURA, FLAURA2, LAURA.» In modern oncology, the choice of therapy for patients with non-small cell lung cancer (NSCLC) depends on molecular genetic testing. There are three groups of patients and corresponding classes of drugs for the treatment of metastatic NSCLC: targeted therapy for 35% of patients with positive molecular genetic markers, chemotherapy or chemotherapy with immunotherapy for 35% of patients with negative markers, and immunotherapy or immunotherapy with chemotherapy for PD-L1+ tumors. The report also reviewed the results of the FLAURA, FLAURA2, and LAURA studies.
Leave a comment